Hongbiao Huang

List of Publications by Year in Descending Order

52 papers	1,660 citations	24 h-index	40 g-index
52 ext. papers	2,005 ext. citations	8.1 avg, IF	4.24 L-index

#	Paper	IF	Citations
52	A SIX1 degradation inducer blocks excessive proliferation of prostate cancer.. *International Journal of Biological Sciences*, **2022**, 18, 2439-2451	11.2	1
51	Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis. *Cell Death and Disease*, **2021**, 12, 456	9.8	7
50	A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance. *Oncogene*, **2021**, 40, 4291-4306	9.2	3
49	USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 201	12.8	4
48	The deubiquitinating enzyme USP15 stabilizes ER and promotes breast cancer progression. *Cell Death and Disease*, **2021**, 12, 329	9.8	5
47	Selective degradation of AR-V7 to overcome castration resistance of prostate cancer. *Cell Death and Disease*, **2021**, 12, 857	9.8	2
46	USP10 exacerbates neointima formation by stabilizing Skp2 protein in vascular smooth muscle cells. *Journal of Biological Chemistry*, **2021**, 297, 101258	5.4	1
45	Targeting ER degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment. *International Journal of Biological Sciences*, **2020**, 16, 2192-2204	11.2	4
44	Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. *Theranostics*, **2020**, 10, 3366-3381	12.1	29
43	USP10 deletion inhibits macrophage-derived foam cell formation and cellular-oxidized low density lipoprotein uptake by promoting the degradation of CD36. *Aging*, **2020**, 12, 22892-22905	5.6	2
42	ER is a target for butein-induced growth suppression in breast cancer. *American Journal of Cancer Research*, **2020**, 10, 3721-3736	4.4	3
41	Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation. *European Journal of Pharmacology*, **2020**, 883, 173366	5.3	8
40	Deubiquitination of CD36 by UCHL1 promotes foam cell formation. *Cell Death and Disease*, **2020**, 11, 636	9.8	7
39	Deubiquitination and stabilization of estrogen receptor by ubiquitin-specific protease 7 promotes breast tumorigenesis. *Cancer Letters*, **2019**, 465, 118-128	9.9	38
38	Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-B activity in hepatocellular carcinoma. *Cell Death and Disease*, **2019**, 10, 719	9.8	15
37	Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC. *European Journal of Pharmacology*, **2019**, 856, 172409	5.3	14
36	Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 220	12.8	36

35	USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. *Cell Discovery*, **2019**, 5, 24	22.3	42
34	Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 157	12.8	43
33	Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-B signaling. *EBioMedicine*, **2019**, 43, 188-200	8.8	24
32	MiR-454-3p-Mediated Wnt/catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis. *Theranostics*, **2019**, 9, 449-465	12.1	62
31	Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling. *European Journal of Pharmacology*, **2019**, 846, 1-11	5.3	21
30	Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. *Oncogene*, **2018**, 37, 1896-1910	9.2	61
29	Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer. *Oncogenesis*, **2018**, 7, 75	6.6	40
28	Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor. *Cell Death and Disease*, **2017**, 8, e2585	9.8	70
27	Bilirubin neurotoxicity is associated with proteasome inhibition. *Cell Death and Disease*, **2017**, 8, e2877	9.8	21
26	Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer. *Cell Death and Disease*, **2017**, 8, e2803	9.8	31
25	Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation. *Cell Death and Disease*, **2017**, 8, e2913	9.8	12
24	Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition. *Journal of Experimental and Clinical Cancer Research*, **2017**, 36, 79	12.8	17
23	A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers. *Oncotarget*, **2017**, 8, 63232-63246	3.3	32
22	Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. *Oncotarget*, **2017**, 8, 13942-13956	3.3	18
21	Ubiquitin-specific protease 14 regulates cardiac hypertrophy progression by increasing GSK-3 phosphorylation. *Biochemical and Biophysical Research Communications*, **2016**, 478, 1236-41	3.4	22
20	Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. *Oncotarget*, **2016**, 7, 2796-808	3.3	49
19	Combined therapeutic effects of bortezomib and anacardic acid on multiple myeloma cells via activation of the endoplasmic reticulum stress response. *Molecular Medicine Reports*, **2016**, 14, 2679-84	2.9	3
18	Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. *Biochemical Pharmacology*, **2016**, 116, 22-38	6	28

17	A microRNA-mediated decrease in eukaryotic initiation factor 2 promotes cell survival during PS-341 treatment. *Scientific Reports*, **2016**, 6, 21565	4.9	18
16	Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. *Journal of Hematology and Oncology*, **2016**, 9, 129	22.4	15
15	Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition. *Scientific Reports*, **2015**, 5, 9694	4.9	17
14	Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds. *Oncoscience*, **2015**, 2, 457-66	0.8	25
13	A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. *Scientific Reports*, **2014**, 4, 5240	4.9	48
12	Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation. *Toxicology in Vitro*, **2014**, 28, 419-25	3.6	18
11	The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo. *Toxicology Letters*, **2014**, 224, 333-40	4.4	19
10	Anacardic acid induces cell apoptosis associated with induction of ATF4-dependent endoplasmic reticulum stress. *Toxicology Letters*, **2014**, 228, 170-8	4.4	31
9	Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. *Clinical Cancer Research*, **2014**, 20, 151-63	12.9	94
8	Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. *Oncotarget*, **2014**, 5, 5453-71	3.3	112
7	Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. *Oncotarget*, **2014**, 5, 9118-32	3.3	56
6	Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. *Cell Reports*, **2013**, 3, 211-22	10.6	77
5	L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. *PLoS ONE*, **2012**, 7, e49062	3.7	63
4	HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. *PLoS ONE*, **2012**, 7, e52576	3.7	21
3	Gambogic acid enhances proteasome inhibitor-induced anticancer activity. *Cancer Letters*, **2011**, 301, 221-8	9.9	56
2	Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. *European Journal of Pharmacology*, **2011**, 658, 242-7	5.3	108
1	Physiological levels of ATP negatively regulate proteasome function. *Cell Research*, **2010**, 20, 1372-85	24.7	107